Shares of Regenxbio Inc. (NASDAQ:RGNX) reached a new 52-week low during trading on Wednesday . The stock traded as low as $7.58 and last traded at $7.65, with a volume of 113,535 shares traded. The stock had previously closed at $7.98.

Several research firms have recently commented on RGNX. Zacks Investment Research upgraded shares of Regenxbio from a “sell” rating to a “hold” rating in a research note on Thursday, April 14th. Morgan Stanley raised their target price on shares of Regenxbio from $34.00 to $36.00 in a research note on Friday, April 8th. Piper Jaffray Cos. restated a “buy” rating and issued a $33.00 target price on shares of Regenxbio in a research note on Tuesday, July 5th. Finally, Chardan Capital restated a “buy” rating on shares of Regenxbio in a research note on Tuesday, May 10th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Regenxbio has a consensus rating of “Buy” and a consensus target price of $28.35.

The company’s 50 day moving average is $10.01 and its 200 day moving average is $11.82. The company’s market capitalization is $195.95 million.

Regenxbio (NASDAQ:RGNX) last posted its quarterly earnings data on Thursday, May 5th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by $0.01. On average, equities analysts forecast that Regenxbio Inc. will post ($2.37) EPS for the current fiscal year.

In other Regenxbio news, insider Fmr Llc sold 33,196 shares of the company’s stock in a transaction dated Thursday, April 28th. The shares were sold at an average price of $11.23, for a total transaction of $372,791.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

REGENXBIO Inc is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.